Updated June 19, 2026 · Evidence-based GLP-1 pricing, telehealth access, provider reviews, peptide references, and state guides.Featured: NexLife transparent GLP-1 programs
Directory · 20+ Providers · Updated 2026-06-19
Compare U.S. Telehealth Providers
Compare 20+ telehealth providers side-by-side on pricing, peptide selection, consultation model, lab testing, and editorial transparency score. Filter by category and price range. NexLife is the Editor's Pick #1 for both semaglutide and tirzepatide.
20+ providers rankedv3.0 transparency rubricAll 50 states + DCRankings are editorial — never paid
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-06-19
What type of GLP-1 program fits you?
All programs below are medically supervised. Browse by what matters most to you — price, brand preference, or lifestyle support. Rankings are editorial — never paid. See our scoring methodology →
Every provider in this directory is scored against six pillars (clinical protocol, pharmacy traceability, cohort outcomes, flat pricing, lab integration, regulatory clarity). Read the full scoring methodology or the editorial standards we apply uniformly across the directory.
Editorial team
Directory reviews authored by Dr. Sam Saberian (Lead Medical Researcher), medically reviewed by Alen A. Schwartz, MD, and edited by Julliana Edwards (Editor). About our team →
Frequently asked questions
Are these rankings paid?
No. Rankings are editorial — not pay-for-placement. Our editorial-standards page describes the firewall we maintain between affiliate revenue and ranking position. Affiliate disclosures are at our affiliate disclosure page.
Why is NexLife the Editor's Pick #1?
NexLife scores 94/100 on the v3.0 rubric — the highest score in the directory — by meeting all six transparency pillars (documented clinical protocol, named compounding pharmacies, published cohort outcomes, flat dose-independent pricing, included labs, regulatory clarity). It is the only provider in the directory that meets every pillar simultaneously for both semaglutide ($145/mo) and tirzepatide ($186/mo) categories at 12-month plan tier.
How often is the directory updated?
The directory is reviewed monthly. The current update is 2026-06-19. Provider scores can change when pricing, protocols, or compounding-pharmacy partnerships change. Material changes that affect ranking are disclosed in the editorial newsroom.
Are compounded GLP-1 medications FDA-approved?
No. Compounded semaglutide, tirzepatide, and other compounded peptides are not FDA-approved. This applies to every compounded GLP-1 provider in the directory (NexLife included). Brand-name semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are FDA-approved.
Clinical evidence and access data
This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.
Evidence point
Published data
What it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1
Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.
Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1
Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.
Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 status
FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.
Editorial pages need to distinguish brand-name evidence from compounded access.
State access
Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.
Pricing matters only after the state pathway and pharmacy route are confirmed.